Logo image of SRXH

SRX HEALTH SOLUTIONS INC (SRXH) Stock Fundamental Analysis

USA - NYSEARCA:SRXH - US08771Y4026 - Common Stock

0.306 USD
+0 (+0.66%)
Last: 9/12/2025, 8:18:30 PM
0.3034 USD
0 (-0.85%)
After Hours: 9/12/2025, 8:18:30 PM
Fundamental Rating

4

Overall SRXH gets a fundamental rating of 4 out of 10. We evaluated SRXH against 40 industry peers in the Consumer Staples Distribution & Retail industry. While SRXH seems to be doing ok healthwise, there are quite some concerns on its profitability. SRXH has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

SRXH had negative earnings in the past year.
SRXH had a negative operating cash flow in the past year.
SRXH had negative earnings in 4 of the past 5 years.
In the past 5 years SRXH reported 4 times negative operating cash flow.
SRXH Yearly Net Income VS EBIT VS OCF VS FCFSRXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

SRXH has a better Return On Assets (11.11%) than 92.50% of its industry peers.
With a decent Return On Equity value of 21.33%, SRXH is doing good in the industry, outperforming 70.00% of the companies in the same industry.
Industry RankSector Rank
ROA 11.11%
ROE 21.33%
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRXH Yearly ROA, ROE, ROICSRXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

Looking at the Profit Margin, with a value of 4.96%, SRXH belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
SRXH's Gross Margin of 37.27% is fine compared to the rest of the industry. SRXH outperforms 77.50% of its industry peers.
In the last couple of years the Gross Margin of SRXH has remained more or less at the same level.
Industry RankSector Rank
OM N/A
PM (TTM) 4.96%
GM 37.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
SRXH Yearly Profit, Operating, Gross MarginsSRXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

SRXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
SRXH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SRXH has been increased compared to 5 years ago.
SRXH has a better debt/assets ratio than last year.
SRXH Yearly Shares OutstandingSRXH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SRXH Yearly Total Debt VS Total AssetsSRXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

SRXH has an Altman-Z score of -27.33. This is a bad value and indicates that SRXH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -27.33, SRXH is doing worse than 92.50% of the companies in the same industry.
There is no outstanding debt for SRXH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.33
ROIC/WACCN/A
WACC7.53%
SRXH Yearly LT Debt VS Equity VS FCFSRXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.99 indicates that SRXH should not have too much problems paying its short term obligations.
SRXH has a better Current ratio (1.99) than 82.50% of its industry peers.
A Quick Ratio of 1.37 indicates that SRXH should not have too much problems paying its short term obligations.
SRXH has a Quick ratio of 1.37. This is amongst the best in the industry. SRXH outperforms 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.37
SRXH Yearly Current Assets VS Current LiabilitesSRXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 107.92% over the past year.
The Revenue has decreased by -8.12% in the past year.
Measured over the past years, SRXH shows a quite strong growth in Revenue. The Revenue has been growing by 17.56% on average per year.
EPS 1Y (TTM)107.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.73%
Revenue 1Y (TTM)-8.12%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%-9.4%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y273.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRXH Yearly Revenue VS EstimatesSRXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
SRXH Yearly EPS VS EstimatesSRXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -10 -20 -30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SRXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 1.15, the valuation of SRXH can be described as very cheap.
Based on the Price/Forward Earnings ratio, SRXH is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
SRXH is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.73, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.15
SRXH Price Earnings VS Forward Price EarningsSRXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRXH Per share dataSRXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SRXH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SRX HEALTH SOLUTIONS INC

NYSEARCA:SRXH (9/12/2025, 8:18:30 PM)

After market: 0.3034 0 (-0.85%)

0.306

+0 (+0.66%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)08-18 2025-08-18
Earnings (Next)11-10 2025-11-10
Inst Owners1.31%
Inst Owner ChangeN/A
Ins Owners8.55%
Ins Owner Change0%
Market Cap4.72M
Analysts82.86
Price Target10.2 (3233.33%)
Short Float %N/A
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.15
P/S 0.14
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-2.43
EYN/A
EPS(NY)0.27
Fwd EY86.67%
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS2.22
BVpS0.52
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 21.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 4.96%
GM 37.27%
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
F-Score5
Asset Turnover2.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.19%
Cap/Sales 0.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.37
Altman-Z -27.33
F-Score5
WACC7.53%
ROIC/WACCN/A
Cap/Depr(3y)14.78%
Cap/Depr(5y)14.84%
Cap/Sales(3y)0.18%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)107.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.73%
EPS Next Y273.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.12%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%-9.4%
Revenue Next Year25%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y61.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y79.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.34%
OCF growth 3YN/A
OCF growth 5YN/A